Treatment of Disorders Occurring in Obstetrics and Gynaecology

Warning

Section Under Review

This page is under development. Please check again later.

Dysmenorrhoea

First Choice: PARACETAMOL OR MEFENAMIC ACID

Second Choice: NAPROXEN

Prescribing Notes:

  • Consider reducing dose of PARACETAMOL to 0.5g four times daily in patients with low body weight (< 50kg), renal/hepatic impairment or glutathione deficiency (chronic malnourishment, chronic alcoholism).
  • For optimal effect, regular analgesics should be initiated just before anticipated onset of menstruation.
  • If contraception is required then combined oral contraceptives should be considered since they may prevent the pain of dysmenorrhoea. Please refer to the Contraceptives section.

Menorrhagia

First Choice: LEVONORGESTREL releasing intrauterine system (Mirena®) (if at least 12 months treatment expected)

Second Choice: TRANEXAMIC ACID or oral NSAID (MEFENAMIC ACID or NAPROXEN) or combined oral contraceptive.

Third Choice:

Prescribing Notes:

  • For combined oral contraceptives and depot progestogens, please refer to the Contraceptives section.
  • Mirena® is an effective first line treatment for menorrhagia.
  • Women offered Mirena® should be advised of changes in the bleeding pattern, particularly in the first few cycles and maybe lasting longer than 6 months. They should therefore be advised to persevere for at least 6 cycles to see the benefits of treatment.
  • NSAIDs should be preferred to TRANEXAMIC ACID when there is menorrhagia with dysmenorrhoea.
  • Use of NSAIDs and/or TRANEXAMIC ACID should be stopped if symptoms do not improve within 3 menstrual cycles.
  • When a first choice treatment has proved ineffective a second or third line drug treatment option should be considered rather than immediate referral for surgery.
  • TRANEXAMIC ACID is contra-indicated in patients at risk of thromboembolism.

Frequent Irregular Periods

Contraception required:

  • First Choice: combined oral contraceptive

Contraception NOT required:

Prescribing Notes:

  • For combined oral contraceptives, please refer to the Contraceptives section.
  • For postmenopausal women, please refer to Hormone replacement therapy (HRT) for menopausal symptoms.

Endometriosis

First Choice: combined oral contraceptive or MEDROXYPROGESTERONE ACETATE

Second Choice: TRIPTORELIN (Decapeptyl SR®) (on specialist advice)

Prescribing Notes:

  • For combined oral contraceptives, please refer to the Contraceptives section.
  • Symptoms, particularly pelvic pain and abnormal uterine bleeding, may be better controlled if the combined oral contraceptive is taken continuously for 90 days.
  • Side–effects of gonadorelin analogues related to the inhibition of oestrogen production may be reduced by hormone replacement (e.g. with an oestrogen and a progestogen or with tibolone).

Uterine Fibroids

Specialist initiation (S1)

ULIPRISTAL ACETATE 5mg tablets (Esmya®)

Prescribing Notes:

  • MHRA Drug Safety Update February 2021:
    'Ulipristal acetate 5mg (Esmya®): further restrictions due to risk of serious liver injury'
  • Although the temporary license suspension has been lifted, this medicine should only be used for intermittent treatment of moderate to severe symptoms of uterine fibroids before menopause and when surgical procedures (including uterine fibroid embolisation) are not suitable or have failed.
  • Further information, including liver function monitoring, is available via the MHRA link provided above.
  • Please note: there are no concerns with emergency contraceptive ellaOne® (ULIPRISTAL ACETATE 30mg single dose) at this time.

Lichen Sclerosus

First Choice: CLOBETASOL PROPIONATE (Dermovate®)

Prescribing Notes:

  • Moisturisers are helpful for softening and protecting the skin.
  • Emulsifying ointment or Dermol® may be useful as soap substitutes. Lubricants may also be beneficial if sexual intercourse is painful.

Infertility

To be initiated and prescribed on specialist advice:

Prescribing Notes:

  • All infertility drugs, including CLOMIFENE CITRATE, should be initiated and prescribed by hospital specialists.

Persistent Breast Pain (Mastalgia)

Please refer to the BNF treatment summary.

Premenstrual Tension

First choice: no drug treatment

Prescribing Notes:

  • Hormonal manipulation may be useful e.g. combined oral contraceptive or Depo-Provera®, in some circumstances.
  • There is no convincing evidence of a useful drug treatment for PMT.

Galactorrhoea

First Choice: no drug treatement

Prescribing Notes:

  • Most cases of galactorrhoea are mild and resolve spontaneously.
  • BROMOCRIPTINE can be useful for patients with persistent galactorrhoea following specialist referral and investigation. Consider drug causes e.g. CHLORPROMAZINE, METOCLOPRAMIDE, CIMETIDINE, DOMPERIDONE.

 

Polycystic Ovarian Syndrome

First choice: combined oral contraceptive; Please refer to the Contraceptives section.

If hirsutism:

Prescribing Notes:

  • In accordance with CSM guidance, Dianette® should be withdrawn 3 to 4 cycles after the treated condition has completely resolved.
  • Polycystic ovarian syndrome consists of a collection of symptoms some or all of which may not require drug treatment; weight reduction is the first essential line of management for obese patients.
  • For acne, please refer to the Acne and Rosacea section.
  • If there are concerns regarding infertility, both the male and female partners should be referred to a clinic. Ovulation induction with anti-oestrogens may be required and should only be prescribed with appropriate monitoring.
  • As with Gedarel®, Femodene® contains a less androgenic progestogen and may be used instead of Gedarel® in women with hirsutism or acne.

Problems in Early Pregnancy

Prescribing Notes:

  • Medical management of non–viable pregnancy (including incomplete miscarriage) and induction of abortion is performed in specialist licensed units. Currently first choice is MIFEPRISTONE followed by a prostaglandin.
  • Methotrexate is first choice medical treatment for ectopic pregnancy under hospital supervision (off-label).

NHSL Joint Adult Formulary Key

To indicate the category of a formulary medicine, updated sections adopt the following key:

Preferred list (P): First-line formulary choices.

Total list (T): Alternative choices when preferred list options not effective/not tolerated, or not indicated.

Specialist initiation (S1): Specialist initiation, or on the advice of a Consultant or Specialist Practitioner in this therapeutic area. Continuation in primary care is acceptable.

Specialist use only (S2): Supply via hospital, Homecare Service or a hospital based prescription (HBP) for dispensing by community pharmacy. Not prescribed in primary care setting.

Editorial Information

Last reviewed: 31/01/2022

Next review date: 31/01/2025

Author(s): NHSL.

Version: Please refer to the introduction section for an explanation of the review dates above.

Approved By: ADTC

Reviewer name(s): ADTC.